News Quantified

VRNA – verona pharma plc - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight

Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight

Verona Pharma Announces December 2024 Investor Conference Participation [Yahoo! Finance]

Verona Pharma Announces December 2024 Investor Conference Participation

Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman [Yahoo! Finance]

Canaccord Genuity

Form 4 Verona Pharma plc For: Dec 04 Filed by: ZACCARDELLI DAVID

Form 4 Verona Pharma plc For: Dec 04 Filed by: Hahn Mark W

Form 4 Verona Pharma plc For: Nov 27 Filed by: Hahn Mark W

Form 4 Verona Pharma plc For: Nov 27 Filed by: ZACCARDELLI DAVID

Form 4 Verona Pharma plc For: Nov 25 Filed by: Hahn Mark W

Top News Gainers

1/10 Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy 26.2%

1/18 VERONA PHARMA P/S (NASDAQ: VRNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.6%

3/31 Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD 12.6%

4/21 VERONA PHARMA P/S (NASDAQ: VRNA) had its price target lowered by analysts at Wedbush from $60.00 to $50.00. They now have an "outperform" rating on the stock. 12.0%

9/3 Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference 8.7%

10/17 Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD 7.6%

11/16 VERONA PHARMA P/S (NASDAQ: VRNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.9%

5/7 Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019 5.2%

4/16 Verona Pharma plc: Results of AGM 4.8%

2/14 Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research 4.2%

Top News Decliners

1/13 Verona Pharma shares shoot higher on Phase 2 trial of respiratory drug [MarketWatch] -28.8%

4/30 Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020 -28.3%

3/16 2019 Annual Report and Accounts and Notice of AGM -17.8%

3/7 VERONA PHARMA P/S (NASDAQ: VRNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.7%

1/13 VERONA PHARMA P/S (NASDAQ: VRNA) had its price target raised by analysts at Wedbush from $58.00 to $60.00. They now have an "outperform" rating on the stock. -10.9%

4/30 Verona Pharma down 30% on uncertainty with Phase 3 ensifentrine study [Seeking Alpha] -9.2%

2/27 Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update -7.7%

7/29 VERONA PHARMA P/S (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock. -6.8%

8/5 Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD -6.6%

4/1 VERONA PHARMA P/S (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $60.00 price target on the stock. -6.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day